IRIS
MOR, Marco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.912
AS - Asia 8.755
EU - Europa 8.529
SA - Sud America 1.439
AF - Africa 455
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 8
Totale 30.106
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.616
SG - Singapore 3.660
CN - Cina 2.895
IT - Italia 1.665
FI - Finlandia 1.428
IE - Irlanda 1.288
BR - Brasile 1.155
SE - Svezia 1.144
DE - Germania 903
HK - Hong Kong 751
UA - Ucraina 644
VN - Vietnam 531
NL - Olanda 347
ZA - Sudafrica 306
TR - Turchia 270
GB - Regno Unito 258
CA - Canada 197
RU - Federazione Russa 186
AT - Austria 185
IN - India 156
FR - Francia 117
AR - Argentina 107
CI - Costa d'Avorio 89
BE - Belgio 84
BD - Bangladesh 83
JP - Giappone 68
PL - Polonia 68
ES - Italia 61
MX - Messico 58
ID - Indonesia 56
KR - Corea 54
EC - Ecuador 53
CZ - Repubblica Ceca 46
IQ - Iraq 40
PK - Pakistan 32
LT - Lituania 26
VE - Venezuela 26
CO - Colombia 23
PY - Paraguay 22
CL - Cile 20
JO - Giordania 18
MA - Marocco 16
UZ - Uzbekistan 16
PE - Perù 13
AZ - Azerbaigian 12
NP - Nepal 12
UY - Uruguay 12
IL - Israele 11
KE - Kenya 11
RO - Romania 11
IR - Iran 9
SA - Arabia Saudita 9
BY - Bielorussia 8
EG - Egitto 8
ET - Etiopia 8
MY - Malesia 8
PA - Panama 8
EU - Europa 7
HN - Honduras 7
HU - Ungheria 7
OM - Oman 7
PS - Palestinian Territory 7
TN - Tunisia 7
AE - Emirati Arabi Uniti 6
KG - Kirghizistan 6
NI - Nicaragua 6
SY - Repubblica araba siriana 6
BG - Bulgaria 5
BO - Bolivia 5
CH - Svizzera 5
CR - Costa Rica 5
DO - Repubblica Dominicana 5
EE - Estonia 5
HR - Croazia 5
LB - Libano 5
NO - Norvegia 5
TH - Thailandia 5
AL - Albania 4
CY - Cipro 4
DZ - Algeria 4
JM - Giamaica 4
KZ - Kazakistan 4
LU - Lussemburgo 4
MD - Moldavia 4
AU - Australia 3
BH - Bahrain 3
GY - Guiana 3
LV - Lettonia 3
SI - Slovenia 3
SK - Slovacchia (Repubblica Slovacca) 3
TJ - Tagikistan 3
AM - Armenia 2
AO - Angola 2
BW - Botswana 2
DK - Danimarca 2
NZ - Nuova Zelanda 2
PH - Filippine 2
RS - Serbia 2
SN - Senegal 2
SV - El Salvador 2
Totale 30.091
Salva come PNG Salva come JPEG
Città #
Singapore 1.797
Chandler 1.285
Dublin 1.279
Ashburn 1.226
Dallas 975
Jacksonville 753
Hong Kong 741
Santa Clara 738
Beijing 731
Parma 552
Dearborn 456
Ann Arbor 440
Boardman 420
Nanjing 319
Johannesburg 289
Los Angeles 255
Princeton 248
Munich 237
Izmir 233
New York 232
Shanghai 222
Ho Chi Minh City 210
Wilmington 190
Hefei 179
San Mateo 162
Helsinki 153
Vienna 151
São Paulo 121
Bremen 113
Toronto 113
Shenyang 109
Columbus 106
Milan 105
Hanoi 98
Moscow 98
Nanchang 93
Abidjan 89
Jinan 88
Hebei 86
Kunming 84
Turku 75
Brussels 74
Buffalo 72
The Dalles 69
Bologna 67
Seattle 65
Düsseldorf 63
Tokyo 62
Changsha 60
Council Bluffs 59
Des Moines 58
London 57
Warsaw 55
Guangzhou 53
Jiaxing 49
Brooklyn 47
Tianjin 47
Frankfurt am Main 46
Jakarta 46
Seoul 44
Pune 42
Modena 41
Phoenix 41
Houston 40
Montreal 39
Brescia 38
Woodbridge 38
Stockholm 34
Fremont 33
Rio de Janeiro 33
Chennai 31
Chicago 30
Norwalk 30
Nuremberg 30
Belo Horizonte 29
Denver 29
Haiphong 29
San Francisco 29
Zhengzhou 29
Grafing 24
Hangzhou 24
Orem 24
Atlanta 23
Amsterdam 22
Ankara 22
Brno 22
Da Nang 22
Fuzhou 20
Poplar 20
Campinas 19
Curitiba 19
Dong Ket 18
Ottawa 18
Porto Alegre 18
Amman 17
Boston 17
Brasília 17
Manchester 17
Naples 17
Dhaka 16
Totale 18.005
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 310
Benzisothiazolinone Derivatives as Potent Allosteric Monoacylglycerol Lipase Inhibitors That Functionally Mimic Sulfenylation of Regulatory Cysteines 237
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 219
Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach 208
Antidepressant-like activity and cardioprotective effects of fatty acid amide hydrolase inhibitor URB694 in socially stressed Wistar Kyoto rats 202
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 201
Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line 196
2-Aminobenzimidazoles as new potent H3-antagonists 194
Analysis of Structure-Activity Relationships for MT2 Selective Antagonists by Melatonin MT1 and MT2 Receptor Models 193
Antidepressant-like effects of pharmacological inhibition of FAAH activity in socially isolated female rats 190
Social stress-induced depressive-like symptoms and changes in gut microbial and lipidomic profiles are prevented by pharmacological inhibition of FAAH activity in male rats 189
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 189
Dibasic biphenyl H(3) receptor antagonists: Steric tolerance for a lipophilic side chain. 186
Chemical modification of NSC12 leads to a specific FGF-trap with antitumor activity in multiple myeloma 185
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 184
Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in mice 184
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. 178
Analysis of illicit dietary supplements sold in the Italian market: Identification of a sildenafil thioderivative as adulterant using UPLC-TOF/MS and GC/MS. 178
2-N-Acylaminoalkylindoles: Design and Quantitative Structure-Activity Relationship Studies Leading to MT2-Selective Melatonin Antagonists 176
A catalytic mechanism for cysteine N-terminal nucleophile hydrolases, as revealed by free energy simulations 172
Amino acid derivatives as palmitoylethanolamide prodrugs: Synthesis, in vitro metabolism and in vivo plasma profile in rats 170
Aminobenzimidazoles as new potent H3-antagonists 168
Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction 166
N-Acylethanolamine Acid Amidase (NAAA): Structure, Function, and Inhibition 165
Application of 3D-QSAR in the Rational Design of Receptor Ligands and Enzyme Inhibitors 164
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 162
Cardioprotective effects of fatty acid amide hydrolase inhibitor URB694, in a rodent model of trait anxiety 162
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. 161
Synthesis, biological activity, QSAR and QSPR study of 2/aminobenzimidazole derivatives as potent H3-antagonists 160
5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity 159
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 158
Alchilammidi tricicliche: ligandi selettivi dei recettori melatoninergici MT1 e MT2 156
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 156
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 155
Free-Energy Simulations Support a Lipophilic Binding Route for Melatonin Receptors 154
Metabolic Soft Spot and Pharmacokinetics: Functionalization of C-3 Position of an Eph–Ephrin Antagonist Featuring a Bile Acid Core as an Effective Strategy to Obtain Oral Bioavailability in Mice 154
Chiral Recognition of Flexible Melatonin Receptor Ligands Induced by Conformational Equilibria 153
Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability 152
Structure–Activity Relationships and Mechanism of Action of Eph–ephrin Antagonists: Interaction of Cholanic Acid with the EphA2 Receptor 152
Antiproliferative and proapototic effects of a new combi-molecule on non small cell lung cancer cell lines 151
A critical cysteine residue in monoacylglycerol lipase is targeted by a new class of isothiazolinone-based enzyme inhibitors. 151
4-(1,2-benzisothiazol-3-)alkanoic and phenylalkanoic acids: synthesis and anti-inflammatory, analgesic and antipyretic activities 150
Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 7. Synthesis and Pharmacological Evaluation of 4-Quinolone-3-carboxamides and 4-Hydroxy-2-quinolone-3-carboxamides as High Affinity Cannabinoid Receptor 2 (CB2R) Ligands with Improved Aqueous Solubility 150
A second generation of carbamate-based fatty acid amide hydrolase inhibitors with improved activity in vivo 147
N-Acylethanolamine Acid Amidase (NAAA): Mechanism of Palmitoylethanolamide Hydrolysis Revealed by Mechanistic Simulations 147
Validation of a histamine H3 receptor model through structure–activity relationships for classical H3 antagonists 146
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 146
Design and structure-activity relationship of amino acid derivatives of lithocholic acid as novel EphA2 antagonists 146
Atropisomerism and Conformational Equilibria: Impact on PI3Kδ Inhibition of 2-((6-Amino-9H-purin-9-yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one (IC87114) and Its Conformationally Restricted Analogs 143
Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatment of FGF-Dependent Lung Tumors 143
5-benzylidene-hydantoins as new inhibitors of cell proliferation 142
Discovery of novel FGF trap small molecules endowed with anti-myeloma activity 139
Dibasic non-imidazole histamine H3 receptor antagonists with a rigid byphenyl scaffold. 139
Development of 3-oxo-cholenic derivatives as Eph antagonists able to block in vitro angiogenesis 139
Chapter 9: Natural and Synthetic Agents That Target Intracellular Monoacylglycerol Lipase (MGL) Activity 138
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 137
A New Potent and Selective Histamine H3-Receptor Antagonist, 4(5)-{2-[4(5)-cyclohexylimidazol-2-ylthio]ethyl}imidazole 136
3-Aminoazetidin-2-one Derivatives asN-Acylethanolamine Acid Amidase (NAAA) Inhibitors Suitable for Systemic Administration 136
Synthesis and 3D-QSAR Analysis of H3 Receptor Antagonists Containing a Neutral Heterocyclic Polar Group 135
QSAR study of 2-aminobenzimidazole derivatives as H3 antagonists 135
5-benzylidene-hydantoin UPR 1024 acts as EGFR inhibitor and induces DNA damage in A549 NSCLC cell line 135
Chiral NMR discrimination of the diastereoisomeric salts of the H(3)-antagonist 2-[3-(1H-imidazol-4-ylmethyl)piperidin-1-yl]-1H-benzimidazole. 134
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 133
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer 131
270 Discovery, development and optimization of low molecular weight EPH–ephrin protein–protein inhibitors 131
Design and structure-activity relationships of amino acid derivatives of lithocholic acid as novel EphA2 receptor antagonists. 130
QM/MM modelling of oleamide hydrolysis in fatty acid amide hydrolase (FAAH) reveals a new mechanism of nucleophile activation 130
Application of a SCC-DFTB QM/MM approach to the investigation of the catalytic mechanism of fatty acid amide hydrolase. 130
N-(Anilinoethyl)amide Melatonergic Ligands with Improved Water Solubility and Metabolic Stability 130
Cyclohexylcarbamic Acid 3'- or 4'-Substituted Biphenyl-3-yl Esters of as Fatty Acid Amide Hydrolase Inhibitors: Synthesis, Quantitative Structure-Activity Relationships and Molecular Modelling Studies 129
Toward the Definition of Stereochemical Requirements for MT(2)-Selective Antagonists and Partial Agonists by Studying 4-Phenyl-2-propionamidotetralin Derivatives. 129
Palladium Catalyst Recycling for Heck-Cassar-Sonogashira Cross-Coupling Reactions in Green Solvent/Base Blend 129
Steps towards sustainable solid phase peptide synthesis: use and recovery ofN-octyl pyrrolidone 129
Functional modulation of the human gut microbiome by bacteria vehicled by cheese 128
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 128
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system 128
Clinical perspective for irreversible tyrosine kinase inhibitors in cancer 127
Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis 127
Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists 126
Antioxidant and cytoprotective activity of indole derivatives related to melatonin 126
Development of a GPCR model for SAR interpretation of classical and new H3 antagonists 126
Development and validation of a LC-MS method with electrospray ionization for the determination of the imidazole H(3) antagonist ROS203 in rat plasma. 125
Mannich base derivatives as novel EGFR irreversible inhibitors 124
New strategies to overcome resistance to EGFR tyrosine kinase inhibitors in non small cell lung cancer 123
ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS 123
Biological studies on 1,2-benzisothiazole derivatives. V. Antimicrobial properties of N-alkanoic, N-arylalkanoic and N-aryloxyalkanoic derivatives of 1,2-benzisothiazolin-3-one: QSAR study and genotoxicity evaluation 123
The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment 123
APPLICATION OF COMPUTATIONAL METHODSTO THE DESIGN OF FATTY ACID AMIDE HYDROLASE(FAAH) INHIBITORS BASED ON A CARBAMICTEMPLATE STRUCTURE 122
Experimental and Theoretical Analysis of the Interaction of (±)-cis-Ketoconazole with b-Cyclodextrin in the presence of (+)-L-Tartaric Acid 121
Discovery and development of low molecular weight Eph-ephrin protein-protein inhbi-tors endowed with antiangiogenic activity 121
L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib 121
2-Arylmelatonin analogues: Probing the 2-phenyl binding pocket of melatonin MT1 and MT2 receptors 121
N-(Anilinoethyl)amides: design and synthesis of metabolically stable, selective melatonin receptor ligands 120
HPLC detection ofthioperamide from biological samples and its determination in rat blood and brainafter systemic administration 120
Synthesis and biological assays of new H3-antagonists with imidazole and imidazoline polar groups 120
MT2 selective melatonin receptor antagonists: design and structure-activity relationships 119
Design, Synthesis, and Physicochemical and Pharmacological Profiling of 7-Hydroxy-5-oxopyrazolo[4,3-b]pyridine-6-carboxamide Derivatives with Antiosteoarthritic Activity in Vivo 119
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 119
Combining pharmacology, target hopping and computational medicinal chemistry to discover novel scaffold targeting EPH-ephrin interaction. 119
Molecular Determinants of EphA2 and EphB2 Antagonism Enable the Design of Ligands with Improved Selectivity 118
Totale 15.011
Salva come PNG Salva come JPEG
Categoria #
all - tutte 109.573
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 109.573
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021953 0 0 0 0 0 51 206 40 341 45 213 57
2021/20221.311 24 37 14 121 85 40 149 175 91 102 90 383
2022/20235.095 551 503 311 392 486 607 46 313 1.575 60 188 63
2023/20241.980 109 148 56 68 145 457 166 159 78 124 201 269
2024/20256.618 169 350 436 424 600 739 303 354 836 650 590 1.167
2025/20268.324 1.235 1.584 1.832 1.405 1.951 317 0 0 0 0 0 0
Totale 30.488